



## Fluarix<sup>®</sup> Quadrivalent (influenza vaccine) – Expanded indication

- On January 11, 2018, [GlaxoSmithKline announced](#) the [FDA approval](#) of [Fluarix Quadrivalent \(influenza vaccine\)](#) for active immunization for the prevention of disease caused by influenza A subtype viruses and type B viruses contained in the vaccine in persons aged 6 months and older.
  - Previously, Fluarix Quadrivalent was only approved for use in persons 3 years of age and older.
- The expanded indication was approved based on a clinical study of 1,332 children 6 months through 35 months of age randomized to Fluarix Quadrivalent or a non-influenza control vaccine.
  - Patients in the Fluarix Quadrivalent group demonstrated greater proportions of immune responses as measured by seroconversion rates and antibody titers vs. the control group.
- In children 6 through 35 months of age, the most common ( $\geq 10\%$ ) solicited local adverse reactions were pain (17%) and redness (13%); the most common systemic adverse reactions were irritability (16%), loss of appetite (14%), and drowsiness (13%).
- The recommended dose and schedule for Fluarix Quadrivalent in patients 6 months through 8 years of age not previously vaccinated with an influenza vaccine is two intramuscular injections at least 4 weeks apart. For those who were vaccinated in a previous season, the recommended dose is one or two injections at least 4 weeks apart.
  - The recommended dose for patients  $\geq 9$  years of age is one injection.



OptumRx<sup>®</sup> specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum<sup>®</sup> company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum<sup>®</sup> trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews<sup>®</sup> is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.